These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 10070886

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H, Levesque MA, Clark GM, Diamandis EP.
    Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
    [Abstract] [Full Text] [Related]

  • 7. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
    Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA.
    Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
    [Abstract] [Full Text] [Related]

  • 8. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC, Crommelin MA, Repelaer van Driel OJ, Tutein Nolthenius-Puylaert MC, Vreugdenhil G, Coebergh JW.
    Ned Tijdschr Geneeskd; 1998 Aug 01; 142(31):1772-8. PubMed ID: 9856143
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
    Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.
    Breast Cancer Res; 2008 Aug 01; 10(5):R79. PubMed ID: 18808688
    [Abstract] [Full Text] [Related]

  • 10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 11. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.
    Clin Cancer Res; 2005 May 01; 11(9):3315-9. PubMed ID: 15867229
    [Abstract] [Full Text] [Related]

  • 12. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2009 Sep 15; 15(18):5888-94. PubMed ID: 19723645
    [Abstract] [Full Text] [Related]

  • 13. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.
    Clin Cancer Res; 2004 Nov 15; 10(22):7490-9. PubMed ID: 15569979
    [Abstract] [Full Text] [Related]

  • 14. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2005 Oct 15; 11(20):7311-21. PubMed ID: 16243802
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 16. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Apr 12; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
    Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG.
    Cancer; 2003 Nov 15; 98(10):2125-32. PubMed ID: 14601081
    [Abstract] [Full Text] [Related]

  • 18. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
    Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M.
    Clin Cancer Res; 2000 Feb 15; 6(2):616-21. PubMed ID: 10690547
    [Abstract] [Full Text] [Related]

  • 19. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Feb 15; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 20. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA, Romain S, Look MP, Martin PM, Klijn JG.
    Cancer Res; 2001 Feb 15; 61(4):1421-5. PubMed ID: 11245445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.